Prognose
Analytikernes gennemsnitlige kursmål er 5,47 € (+107,98 %). Medianen er 5,47 € (+107,98 %).
| Køb |
5 |
| Behold |
2 |
| Sælg |
0 |
Diskussioner i communityet
Der er endnu ingen diskussion om dette aktiv.
Start diskussionNyheder Til nyhedsfeedet
Protalix reports strong revenue and profit growth in Q2 2026, stock slightly lower premarket
Protalix increased revenue in the second quarter to $19.9 million (+26.8%) and reported a net profit of $3.8 million (EPS $0.05). Product sales were driven primarily by Elfabrio to Chiesi; the company holds $40.7 million in cash and is debt-free. Management reaffirmed the 2026 revenue guidance but noted variable ordering patterns from partners and a pipeline that is still maturing; top-line data for PRX-115 are expected in H2 2027. The stock fell modestly by 0.41% in premarket trading. » Mere på de.investing.com
Protalix beats revenue expectations but misses EPS and shares plunge
Protalix reported Q4 2025 revenue of $52.74 million versus expected $18.35 million, but missed on earnings per share at -$0.08 (forecast $0.035). The stock fell about 13% in premarket trading after the company reported a net profit swing to a $6.6 million loss for the fiscal year. Higher R&D costs (+51% to $19.6 million) and increased cost of sales weighed on profitability, while sales to Pfizer supported the strong revenue. Protalix expects a $25 million milestone payment and sees opportunities from a potential European approval of a new Elfabrio dosing regimen. » Mere på de.investing.com
Protalix partners with Secarna to develop antisense therapies for rare kidney diseases
Protalix and Secarna have entered a collaboration and option agreement to develop antisense oligonucleotide therapies for rare kidney diseases. Protalix will identify pharmaceutical targets, Secarna will use its AI platform OligoCreator to design candidate molecules, and Protalix will receive an exclusive license option for clinical development and commercialization. The agreement marks Protalix’s first expansion into rare kidney diseases using RNA technologies; financial terms were not disclosed. Protalix also reported a Q3 2025 EPS and revenue miss versus analyst expectations. » Mere på de.investing.com
Protalix misses Q3 2025 earnings forecast, stock falls sharply premarket
Protalix reported Q3 2025 earnings per share of $0.03, missing the $0.07 expectation; quarterly revenue was $17.67 million versus an estimated $17.79 million. The stock fell 13.55% in premarket trading to $1.85. For the first nine months, the company reported revenue growth of 24% to $43.6 million and held $29.4 million in cash; Protalix plans to start a phase 2 study for PRX-115 before year-end with initial results expected in Q3 2027. » Mere på de.investing.com
Protalix and Chiesi seek re-evaluation of negative EMA opinion on Elfabrio
Protalix and Chiesi Global Rare Diseases have requested a re-evaluation of the EMA’s negative opinion on the proposed alternative dosing regimen for Elfabrio. The aim is to approve an additional option of 2 mg/kg every four weeks alongside the existing 1 mg/kg every two weeks for the treatment of adult patients with Fabry disease. The current marketing authorization remains in effect during the procedure; the final decision will be made by the European Commission after the review is completed. Elfabrio carries a warning for hypersensitivity reactions; Protalix will publish quarterly results on November 17. » Mere på de.investing.com
Virksomhedstal
I det seneste kvartal havde Protalix BioTherapeutics en omsætning på 19,36 mio. € og et nettoresultat på 3,5 mio. €
| (EUR) | september 2026 | YoY |
|---|---|---|
| Omsætning | 19,36 mio. | 27,25 % |
| Bruttofortjeneste | 12,4 mio. | 52,78 % |
| Nettoresultat | 3,5 mio. | 74,26 % |
| EBITDA | 4,47 mio. | 88,09 % |
Fundamentale data
| Nøgletal | Værdi |
|---|---|
Markedsværdi | 232,07 mio. € |
Antal aktier | 84,32 mio. |
Højeste/laveste i 52 uger | 2,91 € - 1,50 € |
| Udbytte | Nej |
Beta | 0,01 |
P/E (PE Ratio) | 11,61 |
PEG (PEG Ratio) | -0,02 |
K/I (PB Ratio) | 3,02 |
P/S (PS Ratio) | 3,01 |
Virksomhedsprofil
Protalix BioTherapeutics, Inc., et biofarmaceutisk selskab, fokuserer på udvikling og kommercialisering af rekombinante terapeutiske proteiner baseret på sit proprietære ProCellEx-system til proteinekspression i planteceller i USA, Australien, Canada, Israel, Brasilien, Rusland, Tyrkiet og internationalt. Selskabet tilbyder Elelyso til behandling af Gauchers sygdom. Dets produktpipeline omfatter PRX-102, et terapeutisk proteinkandidatlægemiddel, som befinder sig i sidste fase af kliniske forsøg til behandling af Fabrys sygdom; PRX-110, en proprietær rekombinant form af humant deoxyribonuklease I udtrykt i plantceller, som har gennemført fase IIa kliniske forsøg til behandling af cystisk fibrose; PRX-115, et rekombinant PEGyleret urikase udtrykt i plantceller til behandling af gigt; og PRX-119, et PEGyleret rekombinant humant DNase I-produktkandidat udtrykt i plantceller til behandling af NETs-relaterede sygdomme. Selskabet har aftaler og partnerskaber med Pfizer, Fundação Oswaldo Cruz (Fiocruz) og Chiesi Farmaceutici S.p.A. Selskabet blev grundlagt i 1993 og har hovedkontor i Hackensack, New Jersey.
| Navn | Protalix BioTherapeutics |
| CEO | Dror Bashan |
| Hjemsted | Hackensack,
nj Israel |
| Websted | |
| Sektor | Dagligvarer |
| Branche | Fødevarer |
| Børsnotering | 15.05.1998 |
| Medarbejdere | 226 |
Tickersymboler
| Børs | Symbol |
|---|---|
AMEX | PLX |
Frankfurt | PBDA.F |
Düsseldorf | PBDA.DU |
München | PBDA.MU |